Managers

Ex-Warburg tech investor Ian Chiu joins Owl Ventures

VC-backed Neurana Pharmaceuticals recruits Thompson as president and CEO

Neurana Pharmaceuticals Inc, a specialty pharmaceutical company focused on treating neuromuscular conditions, has appointed Craig Thompson as president and CEO. Previously, Thompson worked at Anthera Pharmaceuticals where he was president and CEO. Neurana's backers include Sofinnova Ventures, New Leaf Venture Partners, H.I.G. BioHealth Partners, Longitude Capital and MagnaSci Ventures.

Ascentage Pharma takes in about $150 mln

China and Rockville, Maryland-based Ascentage Pharma, a biopharmaceutical company focused on developing apoptosis-targeted therapies for cancers and other diseases, has raised about $150 million in Series C financing, YuanMing Prudence Fund and Oriza Seed Venture Capital led the round with participation from Teng Yue Partners, ArrowMark Partners, HDY International Investment, CTS Capital and CCB International.

HotSpot Therapeutics scores $45 mln Series A

Cambridge, Massachusetts-based HotSpot Therapeutics, a new biotechnology company targeting nature's regulatory hotspots to discover and develop medicines, has raised $45 million in Series A financing. HotSpot's investors include Atlas Venture and Sofinnova Partners.

Healthcare cybersecurity firm CyberMDX fetches $10 mln Series A

New York City-based CyberMDX, a healthcare cybersecurity provider, has closed $10 million in Series A financing. Pitango Venture Capital led the round with participation from OurCrowd Qure.

Polares Medical snags $25 mln

Palo Alto, California-based Polares Medical SA, a medical tech company, has secured $25 million in funding. Decheng Capital led the round with the participation from Endeavour Vision, IDO Investments, Earlybird Venture Capital and Wellington Partners.

Top 10: June venture deals are a mixed bag in various tech sectors

Several investors of Social Capital opt not to invest in next fund: Bloomberg

Social Capital, once one of the hottest VC firms, has seen its fortune dim. At least five investors will not invest in Social Capital’s next fund, Bloomberg is reporting. The firm has seen a number of defections as Social Capital has postponed fundraising at least three times in the past year, the story said. Social Capital’s $600 million fund, closed in 2015, is 90 percent committed, Bloomberg said.

Monthly recap of fund briefs, as of July 16

Crosslink closes eighth fund with $275 mln

Crosslink Capital announced it closed its eighth fund, which was oversubscribed, with $275 million in commitments. The early-stage firm, which has offices in San Francisco and Palo Alto, California, had targeted to raise $250 million, according to a regulatory filing in November. The firm had raised $170 million for its previous fund, which closed in February 2015.